DGX
Quest Diagnostics insider trading
Health Care · Heavy selling
Close · Oct 5, 2026
$232.22
+31.8% over 12 months
Share price and insider trades
DGX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$37.3M
Insiders buying0
Insiders selling8
Valuation, profit and volume
P/E (trailing)n/aSector median 24.5
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Quest Diagnostics insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $37.3M. 27 of 30 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales. 96 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 3SEC | J. E. DavisCEO, President | Sell Plan | 10,000 | $242.72 | $2.4M | -4.3% | — |
| Aug 31SEC | Michael E PrevoznikGeneral Counsel | Sell Plan | 16,010 | $242.88 | $3.9M | -4.4% | — |
| Aug 31SEC | Michael E PrevoznikGeneral Counsel | Sell Plan | 6,237 | $243.63 | $1.5M | -4.7% | — |
| Aug 31SEC | Michael E PrevoznikGeneral Counsel | Sell Plan | 430 | $244.51 | $105K | -5.0% | — |
| Jul 29SEC | Mark E DelaneySvp & Chief Commercial Officer | Sell Plan | 1,600 | $235.18 | $376K | -1.3% | — |
| Jun 8SEC | Karthik KuppusamySvp, Clinical Solutions | Sell Plan | 8,147 | $200.00 | $1.6M | +16.1% | — |
| Jun 2SEC | J. E. DavisCEO, President | Sell Plan | 10,000 | $194.14 | $1.9M | +19.6% | — |
| Mar 6SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 5,558 | $206.21 | $1.1M | +12.6% | — |
| Mar 6SEC | Michael E PrevoznikGeneral Counsel | Sell Plan | 3,878 | $206.21 | $800K | +12.6% | — |
| Mar 6SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 2,855 | $206.21 | $589K | +12.6% | — |
| Mar 6SEC | Karthik KuppusamySvp, Clinical Solutions | Sell | 2,628 | $204.86 | $538K | +13.4% | — |
| Mar 4SEC | J. E. DavisCEO, President | Sell Plan | 10,000 | $212.52 | $2.1M | +9.3% | — |
| Mar 4SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 632 | $207.73 | $131K | +11.8% | — |
| Mar 4SEC | Michael E PrevoznikGeneral Counsel | Sell Plan | 526 | $207.73 | $109K | +11.8% | — |
| Mar 4SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 410 | $207.73 | $85K | +11.8% | — |
| Feb 20SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 1,433 | $204.83 | $294K | +13.4% | — |
| Feb 20SEC | Michael E PrevoznikGeneral Counsel | Sell Plan | 1,111 | $204.83 | $228K | +13.4% | — |
| Feb 20SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 958 | $204.83 | $196K | +13.4% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 10,573 | $205.21 | $2.2M | +13.2% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 10,122 | $206.37 | $2.1M | +12.5% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 3,500 | $207.08 | $725K | +12.1% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 1,619 | $208.21 | $337K | +11.5% | — |
| Feb 17SEC | Catherine T. DohertyEvp, Regional Businesses | Sell Plan | 351 | $209.10 | $73K | +11.1% | — |
| Feb 12SEC | Patrick PlewmanSvp For Diagnostic Services | Sell Plan | 5,662 | $204.00 | $1.2M | +13.8% | — |
| Nov 28SEC | J. E. DavisCEO, President | Sell Plan | 41,004 | $192.27 | $7.9M | +20.8% | — |
| Nov 28SEC | J. E. DavisCEO, President | Sell Plan | 9,342 | $191.59 | $1.8M | +21.2% | — |
| Nov 28SEC | J. E. DavisCEO, President | Sell Plan | 4,747 | $192.97 | $916K | +20.3% | — |
| Nov 28SEC | Vicky B GreggDirector | Sell | 1,250 | $191.76 | $240K | +21.1% | — |
| Nov 20SEC | Mark E DelaneySvp & Chief Commercial Officer | Sell Plan | 7,946 | $187.35 | $1.5M | +23.9% | — |
| Oct 24SEC | Gary M PfeifferDirector | Sell | 1,482 | $182.40 | $270K | +27.3% | — |
Insiders at Quest Diagnostics
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| J. E. DavisCEO, President | — | $17.1M | Sep 3, 2026 | — |
| Catherine T. DohertyEvp, Regional Businesses | — | $7.0M | Mar 6, 2026 | — |
| Michael E PrevoznikGeneral Counsel | — | $6.6M | Aug 31, 2026 | — |
| Karthik KuppusamySvp, Clinical Solutions | — | $2.2M | Jul 27, 2026 | — |
| Patrick PlewmanSvp For Diagnostic Services | — | $2.0M | Jul 27, 2026 | — |
| Mark E DelaneySvp & Chief Commercial Officer | — | $1.9M | Jul 29, 2026 | — |
| Gary M PfeifferDirector | — | $270K | May 21, 2026 | — |
| Vicky B GreggDirector | — | $240K | Jul 27, 2026 | — |
| Sam SamadCFO, President | — | — | Jul 27, 2026 | — |
| Timothy L MainDirector | — | — | Jul 27, 2026 | — |
| Robert B CarterDirector | — | — | Jul 27, 2026 | — |
| Wright Lassiter IIIDirector | — | — | Jul 27, 2026 | — |
| Timothy M RingDirector | — | — | May 21, 2026 | — |
| Denise M MorrisonDirector | — | — | May 21, 2026 | — |
| Timothy C WentworthDirector | — | — | May 21, 2026 | — |
| Tracey DoiDirector | — | — | May 21, 2026 | — |
| Luis DiazDirector | — | — | May 21, 2026 | — |
| Michael J DeppeSvp, Corp. Controller & Cao | — | — | Mar 6, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
Common questions about DGX insiders
Are Quest Diagnostics insiders buying DGX stock?
In the past 12 months, 0 insiders reported open-market purchases of DGX worth $0.
Are Quest Diagnostics insiders selling DGX stock?
8 insiders reported sales worth $37.3M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.